Drug Trial Radar · NCT07150806
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 12, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Joshua PalmerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- RayzeBio, Inc.
- First posted
- Sep 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving RYZ101 may be safe, tolerable and/or effective in treating patients with progressive or recurrent intracranial meningioma.
Conditions
- Recurrent Meningioma
Interventions
Actinium Ac 225 DOTATATE RYZ101Drug
Given IV
Biospecimen CollectionProcedure
Undergo blood and urine sample collection
Computed TomographyProcedure
Undergo CT scan
Echocardiography TestProcedure
Undergo echocardiography
Gallium Ga 68-DOTATATERadiation
Given IV
L-lysine/L-arginine-containing Amino AcidDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
Multigated Acquisition ScanProcedure
Undergo MUGA scan
Positron Emission TomographyProcedure
Undergo PET scan
Somatostatin Receptor Positron Emission TomographyProcedure
Undergo SSTR PET scan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: At 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.